$VKTX

Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its main program, VK2735, is a dual GLP-1 and GIP receptor agonist being developed as subcutaneous and oral treatments for metabolic disorders such as obesity. Viking is advancing subcutaneous VK2735 in Phase 3 studies and has reported Phase 2 results for its oral tablet. Its other programs include VK2809, an oral selective thyroid hormone receptor beta agonist being studied for NASH/MASH, and VK0214, an oral candidate for X-linked adrenoleukodystrophy. Viking also has a preclinical dual amylin and calcitonin receptor agonist program for obesity, and seeks partnering or licensing opportunities for VK0214 and VK5211 before further clinical studies. The company is headquartered in San Diego, California.

AlphAI earnings readThird Quarter 2026 · OCT 28Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

8
1
0

No SEC Form 4 filings for $VKTX in the last 30 days.

See all $VKTX insider activity →
Med

Viking: 3 Key Takeaways for Long-Term Investors

Viking (VKTX) initiated phase 3 trials for its oral weight-loss drug VK2735, showing potential for less frequent dosing. The company raised $960M to support trials and commercial prep. Management highlights competitive advantages in dosing flexibility.

Should You Trim Or Add To Your Viking Therapeutics Position?

Viking Therapeutics (VKTX), valued at $3.45B, is focused on obesity drug VK2735 in Phase 3 trials. Its stock fell 28.3% over a year. Cash reserves, $705M after debt, may last 15 months at current spending. Operating losses grew to $649M. Investors bet on VK2735's success, with $2.74B attributed to drugs without sales.

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

Viking Therapeutics (VKTX) presented clinical data from its VK2735 obesity program at ObesityWeek 2026. In a Phase 2 trial, 74% of participants improved by at least one BMI category after 13 weeks, with significant reductions in cardiometabolic markers. The company also shared baseline data from its ongoing Phase 3 VANQUISH-2 study. VK2735 is a dual GLP-1 and GIP receptor agonist being developed for obesity and metabolic disorders.

VKTX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 9 news stories mentioning VKTX (Viking Therapeutics, Inc.). Coverage has skewed bullish: 8 bullish, 1 neutral, and 0 bearish.

Recent VKTX coverage spans financial news, technology and earnings.

What's driving VKTX

AlphAI scores every news story that mentions VKTX with an AI model for sentiment and relevance, and aggregates insider trades from Viking Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VKTX

Score
$VKTXMedAI 8/10

Viking: 3 Key Takeaways for Long-Term Investors

Viking (VKTX) initiated phase 3 trials for its oral weight-loss drug VK2735, showing potential for less frequent dosing. The company raised $960M to support trials and commercial prep. Management highlights competitive advantages in dosing flexibility.

Should You Trim Or Add To Your Viking Therapeutics Position?

Viking Therapeutics (VKTX), valued at $3.45B, is focused on obesity drug VK2735 in Phase 3 trials. Its stock fell 28.3% over a year. Cash reserves, $705M after debt, may last 15 months at current spending. Operating losses grew to $649M. Investors bet on VK2735's success, with $2.74B attributed to drugs without sales.

$VKTXMedClinical / regulatory· topline data

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

Viking Therapeutics (VKTX) presented clinical data from its VK2735 obesity program at ObesityWeek 2026. In a Phase 2 trial, 74% of participants improved by at least one BMI category after 13 weeks, with significant reductions in cardiometabolic markers. The company also shared baseline data from its ongoing Phase 3 VANQUISH-2 study. VK2735 is a dual GLP-1 and GIP receptor agonist being developed for obesity and metabolic disorders.

Viking Therapeutics gains amid report of renewed takeover interest

Viking Therapeutics (VKTX) shares increased 4.1% following a report of renewed takeover interest. The potential suitor is unknown, according to traders, who cited a Betaville alert. Eli Lilly (LLY) was mentioned in the same report, but not as a confirmed bidder. Investors may watch for further developments in potential M&A activity. (349 characters)

Viking Therapeutics Emerges as Potential Dark Horse in Weight-Loss Drug Race Amid Eli Lilly’s Dominance

Viking Therapeutics (VKTX) is emerging in the weight-loss drug market with VK2735, showing promising results in early trials. Eli Lilly reported strong Q3 earnings, driven by Zepbound, and raised full-year revenue guidance. Viking's stock could rally if late-stage data confirms efficacy. The weight-loss market is competitive, but Viking's dual-formulation strategy may help it carve out a position.

Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?

Eli Lilly (LLY) raised its 2026 sales forecast to $91B-$92B, up from $85B-$87B, driven by strong Q3 revenue growth of 39% and Zepbound sales up 49%. Viking Therapeutics (VKTX) is developing VK2735, a weight-loss drug with promising Phase 2 results, aiming to compete in the growing obesity market. LLY's diversified pipeline and strong lineup may help it navigate competition.

Mid-cap biotech catalysts: FDA dates, earnings, and pipeline data to watch

Five mid-cap biotechs are highlighted with upcoming catalysts. Cytokinetics (CYTK) awaits an FDA decision on Nov 14. Arrowhead (ARWR) reports earnings on Nov 12, while Ionis (IONS) saw a post-earnings sell-off. Crispr (CRSP) and Viking (VKTX) have undated catalysts. CYTK's Q3 revenue was $47.6M, beating estimates. ARWR's consensus EPS is -1.55, and IONS beat EPS and revenue estimates. CRSP showed Phase 1b data, and VKTX's next earnings are tentatively Feb 10, 2027.

$LLYHighAI 8/10

Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher

Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.

UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

UBS initiated coverage of Viking Therapeutics (VKTX) with a buy rating and a $94 price target, citing potential 250% upside. The firm highlights Viking's experimental weight loss drug, VK2735, which showed promising results in clinical trials, including significant weight reduction. Viking is also developing an oral version of the drug and has raised $548 million in recent financing. However, the company faces risks, including competition and the need for further clinical success.

Related tickers